Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Farmers Insurance
Moodys
US Army
Medtronic
Harvard Business School
Merck
Chinese Patent Office
Colorcon

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 062801

« Back to Dashboard

NDA 062801 describes CLINDAMYCIN PHOSPHATE, which is a drug marketed by Perrigo Uk Finco, Fougera Pharms, Abraxis Pharm, Alvogen Inc, Bedford, Bristol Myers Squibb, Fresenius Kabi Usa, Igi Labs Inc, Loch, Marsam Pharms Llc, Mylan Labs Ltd, Sagent Pharms, Solopak, Teva Parenteral, Watson Labs, West-ward Pharms Int, Boca Pharma Llc, Fougera Pharms Inc, G And W Labs Inc, Glasshouse Pharms, Novast Labs Ltd, Perrigo New York, Taro Pharm Inds, Teligent Pharma Inc, Vintage Pharms, Wockhardt, Akorn, Actavis Labs Ut Inc, Mylan Pharms Inc, Perrigo Israel, Taro, Tolmar, Actavis Mid Atlantic, Baxter Hlthcare Corp, Akorn Inc, Sandoz Inc, Abbott Labs, and Baxter Hlthcare, and is included in sixty NDAs. It is available from twenty suppliers. Additional details are available on the CLINDAMYCIN PHOSPHATE profile page.

The generic ingredient in CLINDAMYCIN PHOSPHATE is clindamycin phosphate; tretinoin. There are fifty-five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the clindamycin phosphate; tretinoin profile page.
Summary for 062801
Tradename:CLINDAMYCIN PHOSPHATE
Applicant:Alvogen Inc
Ingredient:clindamycin phosphate
Patents:0
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Pharmacology for NDA: 062801
Ingredient-typeLincosamides
Physiological EffectDecreased Sebaceous Gland Activity
Suppliers and Packaging for NDA: 062801
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CLINDAMYCIN PHOSPHATE clindamycin phosphate INJECTABLE;INJECTION 062801 ANDA Alvogen Inc. 47781-462 N 47781-462-69
CLINDAMYCIN PHOSPHATE clindamycin phosphate INJECTABLE;INJECTION 062801 ANDA Alvogen Inc. 47781-463 N 47781-463-69

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 150MG BASE/ML
Approval Date:Jul 24, 1987TE:APRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Farmers Insurance
Cerilliant
Chubb
Harvard Business School
Merck
Johnson and Johnson
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.